Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference19 articles.
1. American Cancer Society (2008). Non-Small Cell Lung Cancer Detailed Guide, 2008. Available at:
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_About_Lung_Cancer_15.asp
. Last update: 24 October 2008. Accessed 29 April 2009.
2. Astra Zeneca Pharmaceuticals, LP (2008). AstraZeneca files marketing application in Europe for EGFR inhibitor gefitinib (IRESSA) in locally advanced pre-treated non-small cell lung cancer. Last update: 2 May 2008. Available at:
http://www.astrazeneca.com/pressrelease/5390.aspx
. Last update: 2008. Accessed 29 April 2009.
3. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR et al. (2001). Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19: 1734–1742.
4. Carney DN . (2002). Lung cancer—time to move on from chemotherapy. N Engl J Med 346: 126–128.
5. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 21: 2237–2246.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献